Platelet glycoprotein (GP) IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor. There is considerable controversy regarding the clinical role of the GPIIb/IIIa PIA1/A2 as a risk factor for myocardial infarction. A summative analysis is performed on the recent previous reports on the GPIIb/IIIa PIA1/A2 and its correlation to myocardial infarction. The metanalysis was performed to assess the correlation between the pattern of GPIIb/IIIa PIA1/A2 polymorphism and myocardial infarction. From 7 available case-control reports, 553 patients and 1,059 controls are evaluated. The overall frequencies of PIA2 allele for the patients and controls are 0.249 and 0.221, respectively. According to this study, 49.4% of sub-jects with PIA2 allele have myocardial infarction while 39.5% of subjects without PIA2 allele have cerebrovascular disease. From overall risk estimation, the subjects with PIA2 alleles have a 1.1 times higher risk to have myocardial infarction. According to this analysis, it is proposed that the pattern of GPIIb/IIIa PIA1/A2 polymorphism does not represent a useful marker of increased risk for myocardial infarction. In addition, the lack of association between the pattern of GPIIb/IIIa PIA1/A2 polymorphism and ethnicity of the patients was demonstrated in this study.
Platelet glycoprotein (GP) IIb/IIIa is a membrane receptor for fibrinogen and von Willebrand factor (1) . Platelet aggregation and thrombosis play a key role in the pathogenesis of unstable coronary syndromes and their ischemic complication (2) . The platelet GP IIb/IIIa receptor represents the final common pathway leading to platelet aggregation (2) . Concerning the pathobiology of thromboembolism at arterial plaques, several matrix components such as collagen fibrils, fibronectin, and von Willebrand factor interact specifically with GP IIb/IIIa, enabling platelet-subendothelium adhesion, particularly at high wall shear rates (3) . Several patients with thromboembolic diseases appear to benefit preferentially from inhibition of GP IIb/IIIa receptors (4) .
Curtin said that the intravenous GP IIb/IIIa antagonists were potent antiplatelet agents that were particularly effective in patients who underwent percutaneous coronary intervention (PCI) (5) . In addition, Kereiakes mentioned that the GP IIb/IIIa blocker abciximab proved both safe and effective in improving outcomes after coronary interventions (4) . The gene encoding GP IIb/IIIIa shows polymorphism (PIA1/A2) (6) . At present, it has been implicated in the pathogenesis of acute coronary syndromes (7) . There are some investigations to determine whether a common variant (PIA2) of the membrane GP IIb/IIIa gene is associated with myocardial infarction (MI) or coronary artery disease (CAD) (8) . A summative analysis was performed on the recent previous reports on the GPIIb/IIIa PIA1/A2 polymorphism and its correlation with myocardial infarction. The metanalysis was performed and presented in this article.
MATERIALS AND METHODS

Data Mining
A literature review was performed on the reports concerning the correlation between the pattern of GPIIb/IIIa PIA1/A2 polymorphism and myocardial infarction using PubMed (www. pubmed.com) as the search engine. The casecontrol studies with complete data on comparison between patients and controls are selected. The allele frequencies reported from all detected reports were recorded and used as primary data for further analysis.
Assessment for the Correlation Between the Pattern of GPIIb/IIIa PIA1/A2 Polymorphism and Myocardial Infarction
The frequencies from all reports were analyzed using the metanalytic method. Briefly, overall allele frequencies in the patients and controls were calculated. The overall risk estimation for having myocardial infarction comparing the subjects who have to do not have T alleles was then performed. The comparison between frequencies was performed using proportional Z test. The correlation between the ethnic group population and the gene frequencies was also assessed using the regression analysis. A p value equal to or less than 0.05 was accepted as statistically significant.
RESULTS
Seven available case-controls reports (8) (9) (10) (11) (12) (13) (14) were selected for further analysis in this study.
The quoted GPIIb/IIIa PIA1/A2 polymorphism pattern is shown in Table 1 . From those seven case-control studies, 1,878 patients and 2,773 controls are evaluated. The overall frequencies of PIA2 allele for the patients and controls are 0.249 and 0.221, respectively. The overall frequency in the patients is slightly nonsignificant higher (1.13 times) than controls (p > 0.05). According to this study, 43.4% of subjects with PIA2 allele have myocardial infarction, while 39.5% of subjects without PIA2 allele have cerebrovascular disease. From overall risk estimation, the subjects with PIA2 alleles have 1.1 times higher risk to have myocardial infarction.
Concerning the gene frequency in the patients of different national group population, the frequency of PIA2 allele ranged from 13.5% to 44.8% with geometric mean equal to 24.3%. There is no significant correlation between the population nationality and the gene frequencies (p > 0.05).
DISCUSSSION
Several polymorphisms of glycoprotein (GP) that relate to thromboembolic diseases have been described (10) . Polymorphism of GPIIb/IIIa PIA1/A2 is shown to be associated with an increased incidence of cardiovascular events (2) . Coronary artery syndrome and ischemic heart diseases have also been mentioned for possible correlation to PIA2 allele of PIA1/A2 (2). However, it is not clear whether this allele is associated with atherosclerotic pathogenesis in ischemic heart diseases, especially myocardial in- farction. There are some previous studies to document the frequency pattern of PIA1/A2 polymorphism in the patients with myocardial infarction. However, there are only a few previous systematic case-control studies. A metanalysis study was performed to investigate the correlation between PIA1/A2 polymorphism pattern and myocardial infarction. The overall frequencies of PIA2 allele for the subjects with myocardial infarction are not significantly different from those of the controls. Although some previous reports (8-10) mentioned the higher PIA2 allele in the patients, this summative analysis does not confirm the prevalence of PIA2 allele in myocardial infarction. In addition, having PIA2 allele is not a risk factor for having myocardial infarction in both patients and controls. These results confirm the conclusion of Ridker and colleagues that the GP IIb/IIIa A2 allele is not associated with myocardial infarction (11) . On the contrary to the conclusion of Anderson and associates (8) , the pattern of GP IIb/IIIa PIA1/A2 polymorphism does not represent a useful marker of increased risk for ischemic heart diseases.
In addition, the correlation between pattern of GP IIb/IIIa polymorphism and nationality in myocardial infarction was studied. A wide range of gene frequency distribution was seen and it demonstrates the lack of association between pattern of GP IIb/IIIa polymorphism and nationality in this study.
